Vaccine: FluMist Quadrivalent
Approval Date: Feb. 29
Protects Against: Influenza
AstraZeneca ($AZN), maker of the nasal spray vaccine FluMist, nabbed FDA approval for a quadrivalent version of the flu vaccine Feb. 29. FluMist Quadrivalent not only covers two strains of influenza A and one strain of influenza B, but it also adds protection against a second strain of influenza B. This should increase efficacy because it gives health experts and vaccine manufacturers another shot at matching a circulating strain with a strain in the vaccine. Plus, the nasal spray appeals to many who shy away from the jab of a needle.
AstraZeneca compared the quadrivalent verision with the trivalent FluMist, finding that both maintained similar safety levels. Adding the extra strain did not affect immune response.
AstraZeneca's FluMist Quadrivalent to hit U.S. market
SLU: Include both strains of influenza B in shot